Liarozole and 13-cis-Retinoic Acid Anti-Prostatic Tumr Activity

Cancer Research

Volumn 53, Issue 13, 1993, Pages 3073-3077

  Stearns, M E ^a   Wang, M ^a   Fudge, K ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; FIBRONECTIN; ISOTRETINOIN; LIAROZOLE; LIAROZOLE FUMARATE; MATRIGEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; INTRAGASTRIC DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR;

ANIMAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CELL ADHESION; CELL DIVISION; CELL SURVIVAL; CHEMOTACTIC FACTORS; COLLAGENASES; DISEASE MODELS, ANIMAL; GELATINASE B; HUMAN; IMIDAZOLES; ISOTRETINOIN; MALE; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0027220644     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. De Coster, R., Wouters, W., Van Ginckel. R., End, D., et al Experimental studies with liarozole (R 75251): an antitumoral agent which inhibits retinoic acid breakdown. J. Steroid Biochem. Mol. Biol., 43: 197-201, 1992.
2. Denis, L. J. Controversies in the management of localised and metastatic prostatic cancer. Eur. J. Cancer., 27: 333-341, 1991.
3. De Coster, R., Van Ginckel, R., van Moorselaar, R. J. A., Schalkers, J. A., et al. Antitumoral effects of R 75251 in prostatic carcinoma: experimental and clinical studies. Proc. Am. Assoc. Cancer Res., 32: 213, 1991.
4. Van Wauwe, J., Coene, M.-C., Goossens, J. Van Nijen, G., Cools, W. and Lauwers, W. Effects of cytochrome P-450 inhibition on the in vivo metabolism of all-trans retinoic acid in rats. J. Pharmacol. Exp. Ther., 252: 365-369, 1990.
5. Bruynseels, J., De Coster, R., Van Rooy, P., Wouters. W., et al R 75251, a new inhibitor of steroid biosynthesis. Prostate, 16: 345-357, 1990.
6. Wang, M., and Stearns, M. E. Isolation and characterization of 3 PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in s.c.i.d. mice. Differentiation, 48: 115-125, 1991.
7. Stearns, M. E., and Wang, M. Regulation of kinesin expression and type IV collagenase secretion in invasive human prostate PC-3 tumor sublines. Cancer Res., 51: 5866-5875, 1991.
8. Stearns, M. E., and Wang, M. Type IV collagenase (72 kDa) expression in human prostate: benign and malignant tissue. Cancer Res., 53: 1-6, 1993.
9. Edward, M., Gold, J. A., and MacKie, R. M. Modulation of melanoma cell adhesions to basement membrane components by retinoic acid. J. Cell Sci., 93: 155-161, 1989.
10. Hendrix, M. J. C., Wood, R., Seftor, E. A., Lotan, D., Nakajima, M., et al. Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor. Cancer Res., 50: 4121-4130. 1990.
11. Stearns, M. E., and Wang, M. Taxol blocks processes essential for prostate tumor cell (PC-3ML) invasion and metastases. Cancer Res., 52: 3776-3781. 1992.
12. Forgue-Lafitte, M. E., Coudray, A. M., Fagot, D., and Mester, J. Effects of ketoconazole on the proliferation and cell cycle of human cancer cell lines. Cancer Res., 52: 6827-6831, 1992.
13. Nakajima, M., Lotan, D., Baig, M. M., Carralero, R. M., Wood, W. R., Hendrix, M. J. C., and Lotan, R. Inhibition by retinoic acid of type IV collagenase and invasion through reconstituted basement membrane by metastatic rat mammary adenocarcinoma cells. Cancer Res., 49: 1698-1706, 1989.
14. End, D. W., Garrabrant, T., Bowden, C., De Coster, R., and Van Ginckel, R. Antimor effects of liarozole in TA3 mammary carcinoma: comparison to retinoic acid. Proc. Am. Assoc. Cancer Res., 33: 158, 1992.
15. Verma, A. K., Shapas, A. G., Rice, H. M., and Boutwell, R. K. Correlation of the inhibition by retinoids of tumor promoter-induced mouse epidermal ornithine decarboxylase activity and skin tumor promotion. Cancer Res., 38: 419-425, 1979.
16. Pollard, M., Luckert, R H. and Sporn, M. Prevention of autochthonous prostate adenocarcinoma in Lobund-Wistar rats by retinoid. Proc. Am. Assoc. Cancer Res., 32: 380, 1991.
17. Pienta, K. J., Nguyen, N. M., and Lehr, J. E. Treatment of prostate cancer in the rat with the synthetic retinoid Fenretinide. Cancer Res., 53: 224-226, 1993.
18. Pawson, B. A. History of retinoids. J. Am. Acad. Dermatol., 6: 577-582, 1982.
19. Brandes, D. Retinoic acid receptor and surface markers. Models for the study of prostatic cancer cells. In: G. P. Murphy, A. A., Sandberg, and J. P. Karr (eds.). The Prostatic Cell: Structure and Function, pp. 207-218. New York: Alan R. Liss, Inc. 1981.
20. Wang, S. Y., LaRosa, G. J., and Gudas, L. J. Molecular cloning of gene sequences transcriptionally regulated by retinoic acid and dibutyryl AMP in cultured mouse teratocarcinoma cells. Dev. Biol., 107: 75-79, 1985.
21. Sporn, M. B., Roberts, A. B., Wakefield, L. M., and Glick, A. B. Growth factors and retinoids in suppression of neoplasia. Proc. Am. Assoc. Cancer Res., 31: 463. 1991.
22. Koch, H. F. Biochemical treatment of precancerous oral lesions: the effectiveness of various analogues of retinoic acid. J. Maxillofac. Surg., 6: 59, 1978.
23. Wong, W. K., Lippman, S. M., Itri, L., et al. Prevention of second malignant tumors in head and neck cancer with 13-cis retinoic acid. Placebo controlled, double-blind randomized trial. Proc. Am. Soc. Clin. Oncol., 9: 171-172, 1990.
24. Meyskens, F. L., Gilmartin, E., Alberts, D. S., et al. Activity of isotretinoin against squamous cell cancers and preneoplastic lesions. Cancer Treat. Rep., 66: 1315-1317, 1982.
25. Chow, J. M., Cheng, A. L., Su, I. J., and Wang, C. H. 13-cis retinoic acid induces cellular differentiation and durable remission in refractory cutaneous Ki-1 lymphoma. Cancer (Phila.), 67: 2490-2495, 1991.
26. Flynn, P. J., Miller, W. J., Weisdorf, D. J., et al. Retinoic acid treatment of acute promyelocyte leukemia: in vitro and in vivo observations. Blood, 62: 1211-1216, 1983.
27. Besa, E. C., Abrahm, J. L., Bartholomew, M. J., et al. Treatment with 13-cis retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of α-tocopherol. Am. J. Med., 89: 739-745. 1990.